Open Versus Robotic Retromuscular Ventral Hernia Repair (ORREO)

February 5, 2024 updated by: Prisma Health-Upstate

Prospective Randomized Control Trial of Open Versus Robotic REtrOmuscular Ventral Hernia Repair (ORREO Trial)

The purpose of this study is to determine how the robotic retromuscular hernia repair compares to the open retromuscular hernia repair for large hernia defects in patients at higher risk of wound complications.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

All patients presenting to the Greenville Health System Hernia Center who meet the inclusion criteria will be considered for enrollment. Patients who qualify and agree to participate will be randomized 1:1 to robotic retromuscular ventral hernia repair or open retromuscular ventral hernia repair. Data to be collected includes the following: demographic information, medical characteristics, medications, medical and surgical history, operative details, hospital stay data, and patient-reported outcomes via a quality of life questionnaire. Post-operative follow-up will occur at 2 weeks, 6 weeks, 6 months, 1 year and 2 years.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Ventral or incisional hernia measuring ≥ 7 cm and ≤ 15 cm.
  • At least one of the following risk factors: Body Mass Index > 30, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, current smoker (within 1 month)

Exclusion Criteria:

  • Current abdominal wall infection
  • Presence of ileostomy, colostomy, or ileal conduit
  • Center for Disease Control wound class 3 or 4
  • Hernia defect < 7 cm or >15 cm
  • Pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: robotic ventral hernia repair (VHR)
Robotic VHR
A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
Active Comparator: open ventral hernia repair (VHR)
Open VHR
An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite outcome of diagnosis of surgical site occurrence or infection, hospital readmission, or hernia recurrence
Time Frame: Through study completion, an average of 2 years
A composite outcome of events which are clinically significant including but not limited to seroma requiring procedural intervention, skin dehiscence, cellulitis, hematoma, skin necrosis, and surgical site infections which may require interventions such as wound care or antibiotic therapy.
Through study completion, an average of 2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
All surgical site occurrences
Time Frame: Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Surgical site occurrences requiring procedural intervention
Time Frame: Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
All surgical site infections
Time Frame: Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Surgical site infections requiring procedural intervention
Time Frame: Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Length of stay at hospital measured in days
Time Frame: Time from procedure until discharge, an expected range of 2 to10 days
Time from procedure until discharge, an expected range of 2 to10 days
Operative time (procedure start to procedure finish measured in minutes)
Time Frame: Day of surgery
Day of surgery
Quality of Life via questionnaire
Time Frame: Baseline and Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Baseline and Post-operatively: 2 weeks, 6 weeks, 6 months, 1 year, 2 years
Cost for hospital charges from billing office
Time Frame: Through study completion, an average of 2 years
Through study completion, an average of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jeremy A Warren, MD, Prisma Health-Upstate

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2016

Primary Completion (Estimated)

December 1, 2024

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

December 15, 2016

First Submitted That Met QC Criteria

December 28, 2016

First Posted (Estimated)

January 2, 2017

Study Record Updates

Last Update Posted (Actual)

February 7, 2024

Last Update Submitted That Met QC Criteria

February 5, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All patients will be entered prospectively into the Americas Hernia Society Quality Collaborative (AHSQC) database.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ventral Hernia

Clinical Trials on robotic ventral hernia repair

3
Subscribe